Q32 Bio INC 8-K filings

Q32 Bio announced positive topline results from its SIGNAL-AA Part B trial for bempikibart and a $200 million public offering, bolstering its financial runway.

Q32 Bio Inc. announced the pricing of its public offering of common stock and pre-funded warrants, expecting to raise approximately $187.6 million.

Q32 Bio announced topline results from its Phase 2a trial of bempikibart for alopecia areata, showing robust clinical activity and a favorable safety profile.

Q32 Bio announced positive 36-week topline results from Part B of its SIGNAL-AA clinical trial for bempikibart in alopecia areata, showing a 35.3% mean reduction in SALT score.

Q32 Bio Inc. held its Annual Meeting of Stockholders on June 12, 2026, where shareholders elected directors, ratified the appointment of auditors, and approved executive compensation.

Q32 Bio Inc. announced a $55 million private placement of common stock and pre-funded warrants to accredited investors, aiming to advance clinical trials and support general corporate purposes.

Q32 Bio announced its first-quarter 2026 financial results, highlighting progress in its Phase 2a trial for bempikibart and a strengthened financial position.

Q32 Bio Inc. has filed a prospectus supplement to raise up to $75 million in additional capital through an at-the-market equity offering program.

Q32 Bio Inc. has initiated an at-the-market equity offering program to sell up to $14.2 million of common stock through Cantor Fitzgerald & Co.

Mark Iwicki has withdrawn his resignation from Q32 Bio Inc.'s Board of Directors, effective immediately, and will continue as Chair of the Board and Compensation Committee.

Q32 Bio sold its ADX-097 asset to Akebia Therapeutics for an upfront payment, milestone payments, and royalties, extending its cash runway into the second half of 2027.

Q32 Bio announced Q3 2025 financial results and a corporate update, highlighting completed enrollment in its SIGNAL-AA Phase 2a trial and an extended cash runway into 2027.

Q32 Bio Inc. announced the completion of enrollment for Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in alopecia areata, exceeding its target with 33 patients.

Q32 Bio Inc. announced its second quarter 2025 financial results, reporting a reduced net loss and extending its cash runway into 2027, while advancing its lead alopecia areata program.

Q32 Bio Inc. announced the resignation of its Chief Medical Officer, Jason Campagna, M.D., Ph.D., and the appointment of Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer, effective July 9, 2025.

Q32 Bio Inc. announced that its stockholders approved an amendment to the Certificate of Incorporation to limit the liability of certain officers, along with the election of Class I directors and other key proposals, at its 2025 Annual Meeting.

Q32 Bio Inc. received a delisting notice from Nasdaq due to non-compliance with minimum stockholders' equity requirements.

Q32 Bio reports first patient dosed in SIGNAL-AA Phase 2a Part B, Fast Track designation granted for bempikibart, and a cash runway into 2H26.

Mark Iwicki, Chair of the Board of Q32 Bio Inc., will resign effective December 31, 2025, to focus on his role as CEO of Inhibikase Therapeutics, Inc.

Q32 Bio announces positive Phase 2a clinical trial data for bempikibart in alopecia areata and provides a corporate update, highlighting continued responses and financial runway into 2H26.

Q32 Bio announces encouraging results from its SIGNAL-AA Part A clinical trial, showcasing bempikibart's potential as a durable treatment for alopecia areata.

Q32 Bio is restructuring to prioritize the advancement of bempikibart for alopecia areata, discontinuing the ADX-097 renal basket trial and reducing personnel to extend its cash runway.

Q32 Bio Inc. provides an update on its clinical programs for bempikibart and ADX-097, along with financial guidance extending into mid-2026.

Q32 Bio reported positive results in an alopecia areata trial but failed to meet the primary endpoint in an atopic dermatitis study, leading to a strategic shift in focus.

Q32 Bio reported its Q3 2024 financial results and provided updates on its clinical programs, including the expected topline data readouts for bempikibart in atopic dermatitis and alopecia areata in December 2024.

Q32 Bio reported its second quarter 2024 financial results, highlighted by the completion of enrollment in a Phase 2 trial for bempikibart in atopic dermatitis and progress in other clinical programs.

Q32 Bio has completed enrollment in its Phase 2 clinical trial for bempikibart in atopic dermatitis, exceeding the initial target due to high patient demand.

Q32 Bio reported its first quarter 2024 financial results, highlighted by the completion of a reverse merger and a $42 million private placement, while also advancing its clinical pipeline.

Homology Medicines and Q32 Bio have finalized their merger, creating a new publicly traded company focused on developing treatments for autoimmune and inflammatory diseases.

Homology Medicines has amended its previous 8-K filing to update the effective date of its 1-for-18 reverse stock split to March 26, 2024, and to announce the approval of its Nasdaq listing application.